AMY2A and chronic kidney disease: •The verified reduced levels of fecal butyrate and AMY2A in CKD4 in comparison to CKD1, support the hypothesis that butyrate synthesis pathways are affected with CKD progression and these changes, may be reflective of changes in the gut barrier integrity.